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The basic phospholipase 4 (PLA,) from venom of the African elapid Nuja nigricollis was previously shown to have 
anti-coagulant and lethal properties, both of which were abolished by treatment with p-bromophenacyl bromide (pBP). 
In the present paper we first report that pBP-treated PLA, is capable of inhibiting the anti-coagulant activity but not 
the lethal activity of native PLA,, thus suggesting that both properties might be independent. We then confirm this evi- 
dence using PL&-specific monoclonal immunoglobulins. One of these, called HSF, neutralized the lethal activity but 
not the anti-coagulant activity, whereas another antibody, called HSPZ, inhibited the anti-coagulant activity but not the 
lethal activity of the PL4. The data presented in this paper are taken as evidence that the anti-coagulant activity is 
not implicated in the lethal effects of basic PL4 from Nuja nigricollis. 
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1. INTRODUCTION 
Snake venom phospholipases A2 (PLA2) belong 
to a family of structurally homologous [l-3] pro- 
teins that exhibit esterase activity (EC 3.1.1.4). 
They display a variety of pharmacological effects 
which sometimes render them highly toxic. Snake 
venom PLA2 can be classified into three groups, 
depending on their toxicity. The first group com- 
prises acidic and neutral PLA2 with little or no tox- 
icity. The second group comprises highly toxic 
PLAz which block acetylcholine release from nerve 
endings [4,5] and/or provoke muscle damage [6]. 
The third group comprises relatively toxic and 
basic (~1~9) PLA2 with strong in vitro anti- 
coagulant activity associated with a marked ability 
to penetrate densely packed phospholipid 
monolayers [7]. Anti-coagulant PLA2 have been 
isolated from Crotalidae [8], Viperidue [9] and 
Elapidue [lo] venoms. The most active of them is 
the basic PLA2 from the African spitting cobra Nu- 
ja nigricollis [7]. 
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The strong anti-coagulant activity was attributed 
to the hydrophobic character of basic PLAz [ 11,121 
and to the amino acid sequence between residues 54 
and 77 [ 131. In the present study we used (i) a 
chemical derivative modified with p-bromophena- 
cyl bromide and (ii) specific monoclonal antibodies 
to demonstrate that the anti-coagulant and lethal 
activities of basic PLAz from Naja nigricollis are 
independent properties. 
2. MATERIALS AND METHODS 
Lyophilized Naja nigricollis venom was supplied by the In- 
stitut Pasteur (Paris, France). Porcine pancreatic PLAz was 
purchased from Boehringer Mannheim (Penzberg, FRG). All 
chemicals were of the purest grade commercially available. 
Purification of basic PLA2 from Naja nigricollis venom was 
performed as previously described [14]. The last step involved a 
reverse-phase high-performance liquid chromatography on a 
butyl large-pore column (4.6 x 250 mm) using an acetonitrile 
gradient in 0.1 Vo trifluoroacetic acid: 28% to 32% CHaCN for 
120 min at a flow rate of 750pVmin. The basic PLAz was 
previously designated as nigexine [14] and its primary sequence 
was recently elucidated (submitted for publication). Modifica- 
tion with p-bromophenacyl bromide (pBP) was carried out as 
previously described [15] and pBP-treated PLAz was purified by 
reverse-phase high-performance liquid chromatography on a 
butyl large-pore column (4.6 x 250 mm) using a 120 min linear 
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acetonitrile gradient (29% to 34%) in 0.1% trifluoroacetic acid, 
at a flow rate of 750 pl/min [16]. Amino acid analysis of pBP- 
treated PLAz indicated the unique loss of, one histidine residue 
per molecule and the molar extinction coefficient at 276.5 nm 
was determined as 45 500. 
Immunization in BALB/c mice consisted of six subcutaneous 
injections, one every two weeks. Each animal was successively 
injected with: (1) 2OOyg PLA2 mixed with Freund’s complete 
adjuvant (1: 1; v/v); (2) 200 peg PLAz mixed with Freund’s in- 
complete adjuvant; (3) 400rg PLA2 mixed with Freund’s in- 
complete adjuvant; (4) 100 pg PLAz in physiological saline; (5 
and 6) 2OOpg PLAz in physiological saline. The fusion pro- 
cedure was carried out according to KGhler and Milstein [17]. 
Hybrid-containing wells were tested by liquid-phase radioim- 
munoassay using ‘2Sl-labelled PLA2. Positive wells were cloned 
by limiting dilution. Monoclonal antibodies were produced in 
ascitic fluids in syngenic BALB/c mice. Antibodies (HSF, 
IgGlx; HSPl, IgGlx; HSP2, IgGZax) were purified in batches 
according to Reik et al. [18] using caprylic acid, followed by am- 
monium sulfate precipitation. The last purification step con- 
sisted of ion-exchange high-performance liquid chromatog- 
raphy on a column of polyvinylimidazole silica-bonded phase, a 
weak anion-exchange resin (SFCC, Neuilly-Plaisance, France). 
The purity of monoclonal antibody preparations was assessed 
by polyacrylamide gel electrophoresis in the presence of SDS 
(Phast System, Pharmacia). 
Calcium clotting time assays [19] were carried out on platelet 
suspensions using standard platelet concentrates purchased 
from CNTS (les Ulis, France). Platelets (3.5 +0.2 x 10’ cells 
per pl) were suspended in saline buffer containing 145 mM 
NaCl, 5 mM KCl, 1 mM NazHPOd, 10 mM glucose and 10 mM 
N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic a id/NaOH 
buffer, pH 7.4 (Hepes-buffered saline). 200 pl of a mixture of 
100 ~1 of the sample to be tested in Hepes-buffered saline and 
100 ~1 of a solution containing 20 mM CaC12 and 0.14 M NaCl, 
were added to 200 pl of the platelet suspension in a 5-ml glass 
test-tube, all solutions being maintained at 37°C. 
Median lethal dose (LDso) determinations were carried out us- 
ing the sequential up-and-down method of Dixon and Mood 
[20]. Female BALB/c mice (20 f 1 g) were injected in the tail 
vein with various amounts of: (i) basic PLA2; (ii) pBP-treated 
PLA2; (iii) pBP-treated PLA2 mixed with native PLAz; or (iv) 
antibody-PLAz complex. Antibodies and pBP-treated PLA2 
were incubated with the basic PLA2 for 4 h at 37°C. Eight mice 
were injected per dose and survivors were counted 48 h after in- 
jection. 
3. RESULTS AND DISCUSSION 
3.1. pBP-treated PLAa: an inhibitor of anti- 
coagulant activity 
The basic PLAz from Naja nigricoflis venom is a 
potent in vitro anti-coagulant factor [7,10,21]. As 
illustrated in fig. lA, the control clotting time of 
platelets was equal to 150 s and a concentration of 
2 x 10e8 M PLA2 was sufficient to double this 
time. Treatment with pBP, a reagent which 
modifies a critical histidine residue at the PLAz ac- 
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Fig.l.(A) Anti-coagulant activity of various PLA2 and of a 
chemical derivative of PLA2, alone or combined. Activities were 
determined as described in B: basic PLA2 from Naja nigricollis 
venom (o), pBP-treated PLA2 (V), porcine pancreatic PLAz 
(0 ), basic PLAl in the presence of 8 x low7 M, pBP-treated 
PLA2 (v), and basic PLAz in the presence of 8 x lo-’ M por- 
cine pancreatic PLA2 (w). (B) Effect of different monoclonal 
antibodies on the anti-coagulant activity of basic PLA2 from 
Naja nigricollis venom. The coagulation times for the platelet 
suspensions (1.7 + 0.2 10’ cells/pi, final concentration) after 
addition of calcium were measured (see section 2): in the 
absence of antibody (o), in the presence of a 50-fold molar ex- 
cess of HSP2 antibody (0), and in the presence of a 500-fold 
molar excess of HSF (0) or HSPl (A) antibody. 
tive site [ 151, resulted in a derivative with l/750 of 
the anti-coagulant activity of native PLAz (fig. 
1A). Two lines of evidence indicated that this 
residual activity was not due to traces of con- 
taminating native PLA2. Firstly, pBP-treated 
PLA2 was highly pure as judged from several 
analytical criterions reported elsewhere [ 141. 
Secondly, its enzymatic activity, if any, was less 
than 0.01% of that of native PLAz [16]. The 
residual anti-coagulant activity of pBP-treated 
PLA2 is likely, therefore, to be an intrinsic proper- 
ty of the molecule. Decreases in anti-coagulant 
after treatment of PLA2 with pBP has also been 
observed by other authors [7]. 
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Strikingly, we observed that pBP-treated ?LAz 
inhibited the clotting effect of native PLA2. In the 
presence of a non-anti-coagulant dose of 
8 x 10v7 M pBP-treated PLA2, a concentration of 
8 x lo-* M of native PLA2 was required to double 
the coagulation time (fig. lA), or, in other words, 
the activity of basic PLA2 preincubated with pBP- 
treated PLAz decreased by 75%. This large change 
indicated that the inhibitory activity was not due to 
contaminating PLA2 but was a genuine property of 
the derivative. We also observed that the anti- 
coagulant activity of native PLA2 was unaffected 
by addition of 8 x 10e7 M porcine pancreatic 
PLA2, a non-toxic PLA2 with weak anti-coagulant 
activity (fig. lA), indicating that inhibition of the 
anti-coagulant effect by pBP-treated PLA2 was 
specific. Interestingly, it was previously shown that 
pBP-treated PLA2 is still able to bind 
phospholipids [21]. Conceivably, the inhibitory 
property of pBP-treated PLAz was due to its ability 
to prevent native PLAz from binding to coagula- 
tion specifying phospholipids [22], perhaps by a 
competitive process. 
Although the anti-coagulant properties of snake 
venom PLA2 have been extensively studied, it is 
not yet clear whether this activity is related to the 
lethal activity of the molecule. We reasoned that if 
both properties are closely linked, pBP-treated 
PLA2 might inhibit the lethal action of the native 
molecule, as it inhibited anti-coagulant activity. 
We therefore injected mice intravenously with 
various amounts of native PLA2 mixed with a 
lOO-fold molar excess of non-toxic pBP-treated 
PLA2 (table 1) and found that the original toxicity 
of native PLA2 remained unchanged (table 1). We 
considered this result as a preliminary indication 
that the lethal and anti-coagulant activities of basic 
PLA2 might be unrelated properties. This possibili- 
ty was subsequently confirmed. 
3.2. Monoclonal antibodies can discriminate 
between anti-coagulant and lethal activities 
of basic PLA2 
Monoclonal antibodies bind to discrete areas which 
can incorporate as many as 16 amino acid residues 
[23], and constitute ideal tools for targetted prob- 
ing of differend regions of protein surfaces. Using 
the procedure of Kohler and Milstein [17], we 
isolated three hybridomas secreting monoclonal 
antibodies designated HSF, HSPl, and HSP2 
which all bind specifically to 1251-labelled basic 
PLAz (not shown). 
We first investigated the effect of each antibody 
on lethality (table 1). In the presence of a 50-fold 
molar excess of HSF, 5 LDso of PLAz could be in- 
jected intravenously in mice without inducing any 
mortality. Clearly, a single monoclonal antibody 
was sufficient to neutralize lethality. This observa- 
tion was all the more interesting as the other two 
antibodies did not exhibit this property since addi- 
tion of a 50- to 500-fold molar excess of either 
HSPl or HSP2 did not change the lethal potency of 
PLAz (table 1). The mechanisms associated with 
the neutralizing property of HSF are unknown. 
We then investigated the effect of the antibodies 
on anti-coagulant activity. As shown in fig. lB, this 
property remained unchanged when PLA2 was in- 
cubated in the presence of a 500-fold molar excess 
of HSF or HSPl . The epitopes recognized by these 
two antibodies were clearly unrelated to the area 
associated with the anti-coagulant property of 
PLAz. In sharp contrast, in the presence of a 
50-fold molar excess of HSP2, anti-coagulant ac- 
tivity decreased dramatically: a concentration of 
4 x 10m7 M of PLAz was required to double the 
coagulation time. In other words the residual 
coagulant activity of the PLAz-HSP2 complex was 
approx. 5% of that of the PLAt alone. The 
mechanisms associated with the capacity of HSF to 
neutralize anti-coagulant activity are as yet 
unknown. However, it will be of interest, in the 
future, to examine whether the epitope recognized 
by this antibody is located within the region com- 
prising residues 54-77, which has been suggested to 
be associated with the anti-coagulant activity of 
basic PLA2 [13]. 
The data reported above clearly show that three 
PLAz-specific monoclonal antibodies have dif- 
ferent properties. Firstly, HSF neutralized lethality 
but not anti-coagulant activity of PLA2. This result 
constituted in itself a strong indication that lethal 
and anti-coagulant activities were independent 
properties. Secondly, HSP2 was observed to be a 
potent inhibitor of anti-coagulant activity but ,did 
not neutralize the lethal potency of PLA2. This 
result agreed with the previous conclusion that the 
two properties were independent, although it 
should be emphasized that the inability of HSP2 to 
neutralize in vivo lethal activity could not be inter- 
preted completely satisfactorily, since the original 
3 
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Table 1 
In vivo toxicity of basic PLAs from Naja nigricoliis venom in the presence of monoclonal 
antibodies or pBP-treated PLAz 
Median lethal dose (in nmol 
phospholipase per kg bodyweight) 
Basic phospholipase 30.2 + 1.1 
Basic phospholipase + HSF mAb >180 
Basic phospholipase + HSPl mAb 30.3 * 1.5 
Basic phospholipase + HSP2 mAb 30.0 i 2.0 
pBP-phospholipase >7100 
Basic phospholipase + pBP-phospholipase 30.0 i 1.9 
The monoclonal antibodies were preincubated with basic PLAz for 4 h at 37°C. The HSF 
antibody was used at a 50-fold molar excess over PLAz, and the HSPl and HSP2 an- 
tibodies were used at a 500-fold molar excess. When mixed with native PLAz, the amount 
of pBP-treated PLA2 used was 3700 nmol per kg bodyweight. The preparations were in- 
jected intravenously in physiological solutions using female BALB/c mice weighing 
20 * 1 g 
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properties of HSP2 could be altered in the blood 
stream by a multiplicity of uncontrolled factors. 
Thirdly, HSPl had no effect on either property of 
PLAz and could be regarded as a negative control. 
4. CONCLUSION 
The two following conclusions could be drawn 
from the present study. Firstly, pBP-treated PLA2 
inhibited the anti-coagulant activity but not the 
lethal property of native PLA2. Secondly, 
monoclonal antibodies could selectively inhibit one 
of the two properties but not both concomitantly. 
These data indicate that the anti-coagulant activity 
is not implicated in the lethal activity of basic PLA2 
from Naja nigricollis. Further work is now re- 
quired to investigate (i) the inhibitory activity of 
pBP-treated PLAz towards other anti-coagulant 
agents; (ii) the effect of the different antibodies on 
the other properties of PLA2, including esterase ac- 
tivity, cytotoxicity [ 14,161 and hemolytic activity 
and (iii) the localization of the different epitopes 
recognized by the monoclonal antibodies. 
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